(NYSEMKT: NSRX) Nasus Pharma's forecast annual earnings growth rate of N/A is not forecast to beat the US Drug Manufacturers - General industry's average forecast earnings growth rate of 50.29%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 61.16%.
Nasus Pharma's earnings in 2026 is -$5,856,000.On average, 5 Wall Street analysts forecast NSRX's earnings for 2026 to be -$12,779,305, with the lowest NSRX earnings forecast at -$19,613,867, and the highest NSRX earnings forecast at -$8,803,521. On average, 5 Wall Street analysts forecast NSRX's earnings for 2027 to be -$11,580,259, with the lowest NSRX earnings forecast at -$15,814,785, and the highest NSRX earnings forecast at -$8,046,229.
In 2028, NSRX is forecast to generate -$7,908,294 in earnings, with the lowest earnings forecast at -$11,927,352 and the highest earnings forecast at -$3,502,476.